These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2015-001625-16||A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of its Effects on the Inflammatory, Fibrosis,Diabetes and Obesity Biomarkers in Subjects with Alström Sy...||2018-06-04||due-trials|
|Exempt||2016-004782-11||A Phase 1/2A Prospective, Dose-Escalation, Open-Label Study of the Safety, Feasibility, and Initial Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Diabetic Foot Ulcer||2019-03-14||not-yet-due|
|Completed, report not yet due Terminated||2016-004823-21||An Open-Label Rollover Study of PBI-4050 in Subjects with Alström Syndrome||2020-05-08||not-yet-due|
|Exempt Terminated||2017-002927-68||A Phase 1/2A, Dose Escalation, Randomized, Placebo Controlled Study of the Safety, Feasibility, and Efficacy of Subcutaneous Plasminogen (Human) 10 for the Treatment of Chronic Tympanic Membrane Perfo...||not-yet-due|